Enhabit, Inc.
NYSE•EHAB
CEO: Ms. Barbara Ann Jacobsmeyer B.S., M.A., P.T.
Sector: Healthcare
Industry: Medical - Care Facilities
Listing Date: 2022-06-23
Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is based in Dallas, Texas.
Contact Information
Market Cap
$695.92M
P/E (TTM)
-151.2
14.9
Dividend Yield
--
52W High
$14.22
52W Low
$6.47
52W Range
Rank59Top 87.6%
2.2
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 2.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025
Financial Dashboard
Q4 2025 Data
Revenue
$270.40M+0.00%
4-Quarter Trend
EPS
-$0.76+0.00%
4-Quarter Trend
FCF
$3.30M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Net Revenue Growth Net service revenue reached $1,060.0M, marking 2.4% growth versus prior year revenue $1,034.8M.
Loss Reduction Milestone Net loss attributable to Enhabit narrowed 97.1% to $(4.6)M, reflecting strong operating income recovery.
Impairment Normalization Goodwill impairment charge fell significantly by 72.4% to $44.7M in 2025, improving reported results.
Strong Operating Cash Operating cash flow rose to $70.7M, up from $51.2M in 2024, supporting liquidity.
Risk Factors
Pending Merger Uncertainty Proposed $1.1B Kinderhook Merger faces closing conditions, regulatory approvals, and potential delays.
Medicare Rate Headwinds 2026 Home Health rule projects an expected 1.3% aggregate decrease in Medicare payment rates.
Labor Cost Pressures Healthcare industry staffing shortages continue to drive labor costs higher, challenging margins.
Regulatory Compliance Risk Highly regulated industry exposes business to litigation, fines, and adverse reimbursement adjustments.
Outlook
Acquisition Investment Planned Plan $25M to $50M investment in strategic acquisitions during 2026 to accelerate growth.
De Novo Expansion Strategy Execute de novo strategy, targeting 3-6 Home Health and 9-12 Hospice openings in 2026.
Payer Innovation Focus Continue Payer Innovation strategy to secure favorable reimbursement rates with Medicare Advantage plans.
Technology Optimization Leverage AI and analytics platform to optimize clinical resource utilization and improve care plans.
Peer Comparison
Revenue (TTM)
$12.49B
$5.93B
$1.06B
Gross Margin (Latest Quarter)
119.2%
83.5%
73.2%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| RAPT | $959.26M | -14.8 | -61.8% | 1.6% |
| EHAB | $695.92M | -151.2 | -0.8% | 42.8% |
| SNDA | $627.09M | -8.9 | -80.8% | 81.6% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.3%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:May 5, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data